Neurodegenerative Disorders
Oral small molecule shows promise in dementia with Lewy bodies
According to results from the exploratory phase 2 SHIMMER clinical trial, a small molecule oligomer antagonist improved outcomes in patients with dementia with Lewy bodies.
IV administration of fasudil safe, well tolerated in ALS
IV administration of fasudil at two separate doses was safe and well tolerated in a small cohort of individuals with suspected or confirmed ALS, according to new research published in The Lancet.
FDA grants breakthrough device designation to blood-based Alzheimer’s biomarker assay
The FDA has granted breakthrough device designation to a blood-based biomarker test to more quickly detect amyloid presence in individuals with suspected Alzheimer’s disease, according to the manufacturer.
Novel small molecule in development for Parkinson’s-related GBA1 mutations
Vanqua Bio has announced its lead candidate for Parkinson’s disease, a small molecule allosteric activator of glucocerebrosidase, will enter clinical development in the first quarter of 2024.
Octave Bioscience gets $30M to advance MS, neurodegenerative treatment platform
A Bay Area-based precision care company has announced $30 million in funding to continue providing care for those with multiple sclerosis and other neurodegenerative diseases.
Positive interim data announced in phase 1/2 trial of gene therapy for Canavan disease
Myrtelle Inc. announced updated findings of the open-label phase 1/2 clinical trial of its recombinant adeno-associated virus vector-based investigational gene therapy for Canavan disease, a fatal genetic disorder in children.
NIH awards Oligomerix $2.49 million to support development of oral Alzheimer's treatment
Biotechnology company Oligomerix announced a $2.49 million award from the NIH to support phase 1b studies of OLX-07010, an oral tau self-association small molecule inhibitor, according to a company press release.